Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Sykes
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Clear Creek Bio
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Sykes is a co-founder of Clear Creek Bio. He owns equity in the privately held company and is a paid consultant for the company. Clear Creek Bio (CCB) is developing dihydroorotate dehydrogenase (DHODH) inhibitors for the treatment of hematologic malignancies. The company is currently focused on developing brequinar for treating leukemia. The research project is studying DHODH inhibitors for the treatment of acute myeloid leukemia. The Partners Committee on Outside Activities review panel evaluated Dr. Sykes’ financial interest in connection with the research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Developing differentiation therapy for the treatment of patients with acute myeloid leukemia
Project Narrative Adults who are diagnosed with acute myeloid leukemia (AML) have only a 25% chance of surviving for five years, and despite scientific advances in understanding AML, we are still using chemotherapy that was developed more than forty years ago and approved in 1973. One hallmark of AML is that the leukemia cells are frozen in an immature state where they continue to multiply without heeding the normal process of maturation. This project seeks to develop new therapy for the treatment of patients with AML, and in particular seeks to develop ?differentiation? therapy, where the goal is to trigger the cells into resuming their normal process of maturation.
Filed on December 07, 2017.
Tell us what you know about David Sykes's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Sykes filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Sykes | Massachusetts General Hospital | Conflict of Interest | Clear Creek Bio | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.